Growing community of inventors

Ober-Hilbersheim, Germany

Olaf Joens

Average Co-Inventor Count = 2.90

ph-index = 3

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 33

Olaf JoensJuergen Daemmgen (7 patents)Olaf JoensRainer Kleemann (6 patents)Olaf JoensAndrea Vollmar (3 patents)Olaf JoensChristian Troetschel (3 patents)Olaf JoensChristoph Schummer (1 patent)Olaf JoensChristoph Matthias Schummer (1 patent)Olaf JoensOlaf Joens (9 patents)Juergen DaemmgenJuergen Daemmgen (12 patents)Rainer KleemannRainer Kleemann (6 patents)Andrea VollmarAndrea Vollmar (3 patents)Christian TroetschelChristian Troetschel (3 patents)Christoph SchummerChristoph Schummer (1 patent)Christoph Matthias SchummerChristoph Matthias Schummer (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Boehringer Ingelheim Vetmedica Gmbh (5 from 306 patents)

2. Other (3 from 832,680 patents)


9 patents:

1. 12011441 - Pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

2. 11413285 - PDE III inhibitors for treatment of asymptomatic heart failure

3. 10537570 - Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

4. 10537588 - Use of pimobendan for the reduction of heart size in mammals suffering from heart failure

5. 10117869 - PDE III inhibitors for treatment of asymptomatic heart failure

6. 9889148 - Use of pimobendan for the reduction of heart size in mammals suffering from heart failure

7. 9463199 - Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure

8. 8980894 - Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure

9. 8664252 - [object Object]

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/7/2025
Loading…